^
No biomarker
Medulloblastoma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
Medulloblastoma
cisplatin + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cisplatin + vincristine + lomustine
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cyclophosphamide
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
vismodegib
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cisplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
etoposide oral
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cyclophosphamide + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
carboplatin + cyclophosphamide + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
CX-4945
Sensitive: B - Late Trials
PTCH1 mutation
Medulloblastoma
vismodegib
Sensitive: C3 – Early Trials
PTCH1 deletion
Medulloblastoma
IPI 926 oral
Sensitive: D – Preclinical
SUFU deletion
Medulloblastoma
sonidegib
Resistant: D – Preclinical
MYC expression
Medulloblastoma
JHU395
Sensitive: D – Preclinical
SMO D477G
Medulloblastoma
itraconazole
Sensitive: D – Preclinical
MYCN amplification
Medulloblastoma
sonidegib
Resistant: D – Preclinical
PTCH1 mutation
Medulloblastoma
sonidegib
Sensitive: D – Preclinical
SUFU mutation
Medulloblastoma
SMO protein inhibitor
Resistant: D – Preclinical
PTCH1 mutation
Medulloblastoma
SMO protein inhibitor
Sensitive: D – Preclinical
SMO D473H
Medulloblastoma
vismodegib
Resistant: D – Preclinical
SMO D473H
Medulloblastoma
IPI 926 oral
Sensitive: D – Preclinical
TP53 mutation
Medulloblastoma
CUDC-907
Sensitive: D – Preclinical
TP53 mutation
Medulloblastoma
AN2025 + panobinostat
Sensitive: D – Preclinical
TP53 mutation
Medulloblastoma
panobinostat
Sensitive: D – Preclinical
TP53 mutation
Medulloblastoma
AN2025
Resistant: D – Preclinical
TP53 mutation
Medulloblastoma
AN2025 + sirolimus
Sensitive: D – Preclinical
MYC amplification
Medulloblastoma
PCM-075
Sensitive: D – Preclinical
MYCN amplification
Medulloblastoma
olaparib + MK-8776
Sensitive: D – Preclinical